Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,632.19
(
-0.61%
)
US TECH 100
23,737.60
(
-0.64%
)
Dow Jones
46,558.47
(
-0.26%
)
Brent Oil
102.01
(
0.77%
)
Bitcoin
73,732.22
(
1.27%
)
News Focus
News Focus
Post# of 257244
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122787
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 135738

Wednesday, 05/29/2013 4:41:10 PM

Wednesday, May 29, 2013 4:41:10 PM

Post# of 257244
AMGN, Astellas ink drug-development/commercialization JV for Japanese market:

http://finance.yahoo.com/news/amgen-astellas-announce-japan-alliance-041200972.html

The JV’s pipeline will consist of the following five AMGN drugs:

• AMG 145 (PCSK9 inhibitor) for CV disease, in phase-3 (phase-2 in Japan)

• AMG 785/Romosozumab for osteoporosis in phase-3

• AMG 102/Rilotumumab for GI cancer in phase-3 (phase-1 in Japan)

• AMG 337 (MET inhibitor) for GI cancer in phase-1

• AMG 103/Blinatumomab (acquired from MITI) for ALL/NHL in phase-2

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now